Lead program: Phase I

Terran Biosciences

Data updated June 27, 2026

3 Drug Candidates

Terran Biosciences is a New York-based drug discovery platform company developing transformative therapeutics for neurological and psychiatric diseases. Founded by CEO Samuel Clark, the company holds over 200 patent applications covering novel formulations of psychedelic compounds including LSD, DMT, psilocybin, and MDMA, and operates clinical programs in schizophrenia and depression. Its AI-enabled neuromelanin MRI software platform NM-101 has received FDA clearance.

Pipeline Intelligence

Developer Momentum

Programme tracker

Active candidates: 3
Active programmes: 3
Lead stage: Phase I
Forecast coverage: 3 of 3

Latest sourced update

Terran Biosciences Pipeline - Idazoxan XR

Jun 27, 2026 - company-website - Terran Biosciences - Idazoxan XR (Alpha-2 Adrenergic Antagonist)

Next known catalyst

Phase I completed

Q4 2027 - Idazoxan XR (Alpha-2 Adrenergic Antagonist) / Idazoxan XR — Phase 1 PK/Safety (NCT05727189) - Confidence: 55%

9 sources0 pipeline-linked trials0 pipeline-linked papers1 Phase I2 Preclinical

Development Programmes

Idazoxan XR (Alpha-2 Adrenergic Antagonist)

Phase I

Neurocognitive Disorders

Enantiomerically pure extended-release idazoxan (alpha-2 adrenergic antagonist). Licensed exclusively from Pierre Fabre (June 2023). Previously tested in 1,000+ patients. Phase 2 PoC showed ~2x symptom improvement vs antipsychotic alone. Solves historical 3-4x daily dosing with once-daily XR formulation. Indications: schizophrenia (adjunctive) + Alzheimer's disease.

Programme Tracker

Neurocognitive Disorders

Primary: US (FDA)

Phase IActive

Forecast

Phase I completed - Likely: Q4 2027

Idazoxan XR Phase 1 study NCT05727189 is active, not recruiting. ClinicalTrials.gov lists 150 estimated participants, multiple extended-release idazoxan formulations, and estimated primary/completion dates in December 2027.

Milestones

partnership

Completed

Actual: Jun 15, 2023

Exclusive worldwide license from Pierre Fabre for idazoxan and portfolio of alpha-2 adrenergic antagonists. Terran completes key development milestones: once-daily XR formulation, first cohort dosed in Phase 1, early PK analysis confirms target profile.

Why it matters: Idazoxan has 1,000+ patient safety database from prior studies and Phase 2 PoC showing ~2x symptom improvement. Extended-release formulation solves the dosing frequency problem that previously limited clinical utility. Pierre Fabre deal provides global rights.

Terran Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan(Press release)[Verified]NCT05727189 — Phase 1 Idazoxan XR(clinical-trial-registry)[Verified]

Recorded Events

Jun 15, 2023: partnership

Evidence Links

ClinicalTrials.gov NCT05727189 - Study of Idazoxan in Healthy Participants

clinical-trial-registry - ClinicalTrials.gov - Mar 18, 2026 - Verified

ClinicalTrials.gov registry for Phase 1 idazoxan XR study; last update posted 2026-03-18.

Terran Announces Pierre Fabre Idazoxan Licensing Deal and Development Milestones

Press release - PRNewswire / Terran Biosciences - Jun 1, 2023 - Verified

Terran announced exclusive global rights to idazoxan and described ongoing Phase 1 evaluation of extended-release forms.

Terran Biosciences Pipeline - Idazoxan XR

company-website - Terran Biosciences - Jun 27, 2026 - Verified

Company website describes Idazoxan XR as an alpha-2 adrenergic antagonist programme for schizophrenia and Alzheimer disease.

TerXT (Xanomeline + Trospium Prodrugs)

Preclinical

Neurocognitive Disorders

Next-generation muscarinic agonist approach: novel prodrugs of xanomeline (M1/M4 agonist) + trospium (muscarinic antagonist). Once-daily oral + multi-month LAI injectable formulation. 505(b)(2) pathway leveraging Cobenfy (KarXT) safety/efficacy database. NOT a psychedelic compound.

Programme Tracker

Neurocognitive Disorders

Primary: US (FDA)

Pre-clinicalActive

Forecast

Regulatory filing submitted

TerXT remains a non-psychedelic schizophrenia prodrug programme; Terran continues to position it for 505(b)(2)-style development, with PK bridging expected around the Cobenfy/KarXT regulatory window.

Milestones

Company milestone

Completed

Actual: May 20, 2024

Terran announces TerXT development: combination prodrugs of xanomeline and trospium with once-daily oral and multi-month LAI injectable formulations. Will pursue accelerated 505(b)(2) approval pathway leveraging Cobenfy's (KarXT) clinical database.

Why it matters: TerXT addresses Cobenfy's key limitations: twice-daily dosing and food restrictions. Once-daily oral + LAI injectable could significantly improve adherence in schizophrenia — a population with notoriously low medication compliance. 505(b)(2) pathway dramatically reduces development cost and timeline.

Terran Announces TerXT for Schizophrenia — 505(b)(2) Pathway(Press release)[Verified]

Recorded Events

May 20, 2024: Company milestone

Evidence Links

Terran Biosciences Pipeline - TerXT

company-website - Terran Biosciences - Jun 26, 2026 - Verified

Company site describes TerXT as xanomeline/trospium prodrugs for once-daily oral and long-acting injectable schizophrenia treatment.

TerXT Combination of Xanomeline and Trospium Prodrugs for Schizophrenia

industry-media - Psychiatric Times - Jan 1, 2024 - Verified

Coverage describes Terran TerXT development strategy and xanomeline/trospium prodrug rationale.

KarXT Competitor Terran Plans TerXT PK Bridging

industry-media - PharmaVoice - Jan 1, 2024 - Verified

Coverage says Terran planned PK bridging studies after KarXT/Cobenfy approval and a 505(b)(2) pathway.

Eplivanserin + Volinanserin (5-HT2A Antagonist Psychedelic Combos)

Preclinical

Major Depressive Disorder (MDD)PTSD

Selective 5-HT2A antagonists (eplivanserin, volinanserin) licensed from Sanofi (Apr 2022) + deuterated volinanserin from Concert Pharmaceuticals (Mar 2022). Phase 3-tested compounds (15,000+ patients, 100+ trials). Fixed-dose combos with psychedelics (psilocybin, LSD) block hallucinations while preserving therapeutic neuroplasticity. Also: monotherapy for Parkinson's psychosis; "trip terminator" tool. UMB exclusive license for combo patents.

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)

Pre-clinicalActive

Forecast

Regulatory filing submitted

Preclinical combo development. Eplivanserin and volinanserin have extensive Phase 3 safety databases (15,000+ patients). Exclusive license from University of Maryland Baltimore (Mar 2022) for psilocybin + 5-HT2A antagonist combination patents and data. 200+ patent applications across 30+ families covering prodrugs of psilocin, LSD, 2C-B, methylone, long-acting MDMA, oral DMT, 5-MeO-DMT.

Milestones

partnership

Completed

Actual: Apr 1, 2022

Exclusive worldwide license from Sanofi for eplivanserin and volinanserin (selective 5-HT2A antagonists). Concert Pharmaceuticals deuterated volinanserin portfolio also acquired (March 2022). UMB psilocybin + 5-HT2A antagonist combination patent portfolio exclusively licensed.

Why it matters: Three licensing deals in one month assemble the full toolkit for non-hallucinogenic psychedelic therapy: 5-HT2A antagonists with 15,000-patient safety databases, deuterated variants for improved PK, and academic IP covering the combination concept. Positions Terran to develop "psychedelic therapy without the trip."

Mysterious Psychedelics Company Terran Strikes Deal with Sanofi(industry-media)[Verified]

ip-milestone

Completed

Actual: Jan 1, 2024

Terran receives notice of allowance for four US patents including world's first new salts and polymorphs of psilocybin (psilocybin HCl, psilocybin edisylate). Psilocybin DMF filed with FDA. 200+ total patent applications across 30+ patent families.

Why it matters: New psilocybin salts + FDA DMF filing enables future 505(b)(2) pathways for psilocybin products once any psilocybin compound receives approval. Combined with the 5-HT2A antagonist portfolio, this creates the IP foundation for non-hallucinogenic psilocybin therapy.

Terran Receives Notice of Allowance for Four US Patents — New Psilocybin Salts(Press release)[Verified]

Recorded Events

Jan 1, 2024: ip-milestone

Apr 1, 2022: partnership